Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma
Authors:
- Mona Al-MaarriMAMona Al-Maarri
- Hans Carlo MaurerHMHans Carlo Maurer
- Markus SchickMSMarkus Schick
- Sabine MaurerSMSabine Maurer
- Rupert ÖllingerRÖRupert Öllinger
- Irene Gonzalez-MenendezIGIrene Gonzalez-Menendez
- Manuela MartellaMMManuela Martella
- Markus ThalerMTMarkus Thaler
- Konstanze PechloffKPKonstanze Pechloff
- Katja SteigerKatja Steiger
- Sandrine SanderSSSandrine Sander
Open Access
- 8 August 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (15)
Abstract
Aberrant activity of the glycoprotein 130 130/JAK/STAT3 (gp130/JAK/STAT3) signaling axis is a recurrent event in inflammation and cancer. In particular, it is associated with a wide range of hematological malignancies, including multiple myeloma and leukemia. Novel targeted therapies have only been successful for some subtypes of these malignancies, underlining the need for developing robust mouse models to better dissect the role of this pathway in specific tumorigenic processes. Here, we investigated the role of selective gp130/JAK/STAT3 activation by generating a conditional mouse model. This model targeted constitutively active, cell-autonomous gp130 activity to B cells, as well as to the entire hematopoietic system. We found that regardless of the timing of activation in B cells, constitutively active gp130 signaling resulted in the formation specifically of mature B cell lymphomas and plasma cell disorders with full penetrance, only with different latencies, where infiltrating CD138 + cells were a dominant feature in every tumor. Furthermore, constitutively active gp130 signaling in all adult hematopoietic cells also led to the development specifically of largely mature, aggressive B cell cancers, again with a high penetrance of CD138 + tumors. Importantly, gp130 activity abrogated the differentiation block induced by a B cell–targeted Myc transgene and resulted in a complete penetrance of the gp130-associated, CD138 + , mature B cell lymphoma phenotype. Thus, gp130 signaling selectively provides a strong growth and differentiation advantage for mature B cells and directs lymphomagenesis specifically toward terminally differentiated B cell cancers.Keywords
Funding Information
- Deutsche Krebshilfe (111305)
- Deutsche Krebshilfe (111944)
- Deutsche Forschungsgemeinschaft (SFB 1335)
- Deutsche Forschungsgemeinschaft (SFB 824)
- Stiftung Charité (UK)
- Deutsche Forschungsgemeinschaft (SFB 841)
This publication has 54 references indexed in Scilit:
- Impact of Interleukin-6 in Hematological MalignanciesTransfusion Medicine and Hemotherapy, 2013
- Preparation of Mouse Embryonic Fibroblast Cells Suitable for Culturing Human Embryonic and Induced Pluripotent Stem CellsJournal of Visualized Experiments, 2012
- Targeting the Interleukin-6/Jak/Stat Pathway in Human MalignanciesJournal of Clinical Oncology, 2012
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signalingJournal of Clinical Investigation, 2011
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- gp130 at the nexus of inflammation, autoimmunity, and cancerJournal of Leukocyte Biology, 2010
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- Forced Dimerization of gp130 Leads to Constitutive STAT3 Activation, Cytokine-independent Growth, and Blockade of Differentiation of Embryonic Stem CellsMolecular Biology of the Cell, 2006
- Tracking germinal center B cells expressing germ-line immunoglobulin γ1 transcripts by conditional gene targetingProceedings of the National Academy of Sciences, 2006
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985